Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Savara ( (SVRA) ).
Savara has released an updated corporate presentation highlighting the development of MOLBREEVI, an investigational inhalation solution for treating aPAP. The presentation details the potential health benefits, market size, and commercial opportunities for MOLBREEVI, while emphasizing the current lack of approved drugs for aPAP. The update signifies Savara’s strategic focus on addressing unmet medical needs and strengthening its position in the rare respiratory disease market.
More about Savara
Savara Inc. is a pharmaceutical company focused on developing new therapies for rare respiratory diseases. Their primary market focus is on treating conditions such as autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease with no approved treatments available in the U.S. or Europe.
YTD Price Performance: -9.45%
Average Trading Volume: 1,414,433
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $477.1M
See more insights into SVRA stock on TipRanks’ Stock Analysis page.